Tags

Type your tag names separated by a space and hit enter

Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16.
Euro Surveill. 2016 Sep 22; 21(38)ES

Abstract

Although widely recommended, influenza vaccination of children is part of the national vaccination programme only in few countries. In addition to Canada and the United States (US), in Europe Finland and the United Kingdom have introduced live attenuated influenza vaccine (LAIV) for healthy children in their programmes. On 22 June 2016, the US Advisory Committee on Immunizations Practices, voted against further use of LAIV due to no observed vaccine effectiveness (VE) over three consecutive influenza seasons (2013/14 to 2015/16). We summarise the results of a nationwide, register-based cohort study (N=55,258 of whom 8,086 received LAIV and 4,297 TIV); all outcome (laboratory-confirmed influenza), exposure (vaccination) and confounding variable data were retrieved from four computerised national health registers, which were linked via a unique personal identity code assigned to all permanent Finnish residents regardless of nationality. Our study provides evidence of moderate effectiveness against any laboratory-confirmed influenza of the quadrivalent LAIV vaccine (VE: 51%; 95% confidence interval (CI): 28-66%) as well as the inactivated trivalent vaccine (VE: 61%; 95% CI: 31-78%) among two-year-olds during the influenza season 2015/16 in Finland. Based on these data, Finland will continue using LAIV for young children in its National Immunisation Programme this coming influenza season.

Authors+Show Affiliations

Vaccine Programme Unit, Department of Health Protection, National Institute for Health and Welfare, Finland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27684447

Citation

Nohynek, Hanna, et al. "Effectiveness of the Live Attenuated and the Inactivated Influenza Vaccine in Two-year-olds - a Nationwide Cohort Study Finland, Influenza Season 2015/16." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 21, no. 38, 2016.
Nohynek H, Baum U, Syrjänen R, et al. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16. Euro Surveill. 2016;21(38).
Nohynek, H., Baum, U., Syrjänen, R., Ikonen, N., Sundman, J., & Jokinen, J. (2016). Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 21(38). https://doi.org/10.2807/1560-7917.ES.2016.21.38.30346
Nohynek H, et al. Effectiveness of the Live Attenuated and the Inactivated Influenza Vaccine in Two-year-olds - a Nationwide Cohort Study Finland, Influenza Season 2015/16. Euro Surveill. 2016 Sep 22;21(38) PubMed PMID: 27684447.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16. AU - Nohynek,Hanna, AU - Baum,Ulrike, AU - Syrjänen,Ritva, AU - Ikonen,Niina, AU - Sundman,Jonas, AU - Jokinen,Jukka, PY - 2016/07/19/received PY - 2016/09/03/accepted PY - 2016/9/30/entrez PY - 2016/9/30/pubmed PY - 2017/4/13/medline KW - immunisation KW - influenza KW - live attenuated vaccine, inactivated vaccine, children KW - vaccines JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin JO - Euro Surveill VL - 21 IS - 38 N2 - Although widely recommended, influenza vaccination of children is part of the national vaccination programme only in few countries. In addition to Canada and the United States (US), in Europe Finland and the United Kingdom have introduced live attenuated influenza vaccine (LAIV) for healthy children in their programmes. On 22 June 2016, the US Advisory Committee on Immunizations Practices, voted against further use of LAIV due to no observed vaccine effectiveness (VE) over three consecutive influenza seasons (2013/14 to 2015/16). We summarise the results of a nationwide, register-based cohort study (N=55,258 of whom 8,086 received LAIV and 4,297 TIV); all outcome (laboratory-confirmed influenza), exposure (vaccination) and confounding variable data were retrieved from four computerised national health registers, which were linked via a unique personal identity code assigned to all permanent Finnish residents regardless of nationality. Our study provides evidence of moderate effectiveness against any laboratory-confirmed influenza of the quadrivalent LAIV vaccine (VE: 51%; 95% confidence interval (CI): 28-66%) as well as the inactivated trivalent vaccine (VE: 61%; 95% CI: 31-78%) among two-year-olds during the influenza season 2015/16 in Finland. Based on these data, Finland will continue using LAIV for young children in its National Immunisation Programme this coming influenza season. SN - 1560-7917 UR - https://www.unboundmedicine.com/medline/citation/27684447/Effectiveness_of_the_live_attenuated_and_the_inactivated_influenza_vaccine_in_two_year_olds___a_nationwide_cohort_study_Finland_influenza_season_2015/16_ L2 - http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22589 DB - PRIME DP - Unbound Medicine ER -